Alkermes plc.ALKSEarnings & Financial Report
Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies (EDT), the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio.
ALKS Q3 2025 Key Financial Metrics
Revenue
$394.2M
Gross Profit
$342.6M
Operating Profit
$89.1M
Net Profit
$82.8M
Gross Margin
86.9%
Operating Margin
22.6%
Net Margin
21.0%
YoY Growth
4.2%
EPS
$0.49
Financial Flow
Alkermes plc. Q3 2025 Financial Summary
Alkermes plc. reported revenue of $394.2M for Q3 2025, with a net profit of $82.8M (21.0% margin). Cost of goods sold was $51.6M, operating expenses totaled $253.5M.
Key Financial Metrics
| Total Revenue | $394.2M |
|---|---|
| Net Profit | $82.8M |
| Gross Margin | 86.9% |
| Operating Margin | 22.6% |
| Report Period | Q3 2025 |
Alkermes plc. Annual Revenue by Year
Alkermes plc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $1.6B).
| Year | Annual Revenue |
|---|---|
| 2024 | $1.6B |
| 2023 | $1.7B |
| 2022 | $1.1B |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $377.5M | $350.4M | $399.1M | $378.1M | $430.0M | $306.5M | $390.7M | $394.2M |
| YoY Growth | 23.9% | 21.8% | -35.4% | -0.7% | 13.9% | -12.5% | -2.1% | 4.2% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $2.14B | $2.12B | $2.21B | $2.16B | $2.06B | $2.08B | $2.25B | $2.33B |
| Liabilities | $933.5M | $869.1M | $922.8M | $863.2M | $590.6M | $570.4M | $628.2M | $596.1M |
| Equity | $1.20B | $1.25B | $1.28B | $1.29B | $1.46B | $1.51B | $1.62B | $1.73B |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $107.2M | $21.1M | $146.0M | $81.6M | $190.4M | $98.8M | $150.2M | $101.7M |
More Companies
AZN
ASTRAZENECA PLC
Revenue
$14.5B
Net Profit
$2.4B
NVS
NOVARTIS AG
NVO
NOVO NORDISK A S
SNY
Sanofi
GSK
GSK plc
TAK
TAKEDA PHARMACEUTICAL CO LTD
ARGX
ARGENX SE
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Revenue
$1.1B
Net Profit
$186.4M
ALC
ALCON INC
Revenue
$2.6B
Net Profit
$176.0M
TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
Revenue
$4.7B
Net Profit
$481.0M